Join
Live feed
·
PRReleasevia Quantisnow
CAMP4 Therapeutics Corporation logo

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

ByQuantisnow·Wall Street's wire, on your screen.
CAMP· CAMP4 Therapeutics Corporation

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CAMP (CAMP4 Therapeutics Corporation) and more on Quantisnow.